8-KLeadership ChangesRegulation FDExhibits & Filings

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (May 14, 2025)

Filed May 14, 2025For Securities:UNH

Summary

UnitedHealth Group Inc. (UNH) announced significant leadership changes via an 8-K filing on May 13, 2025. Effective May 12, 2025, CEO Andrew Witty has stepped down, transitioning to a senior advisor role. Concurrently, the Board of Directors appointed Steve Hemsley, currently the Chair of the Board, as the new Chief Executive Officer. This transition marks a pivotal moment for the company, with a new leader at the helm to guide its future strategic direction. Investors will be keenly interested in Mr. Hemsley's compensation package, which includes a substantial one-time equity award of $60 million in stock options, vesting after three years. While he will not receive an annual cash incentive, his base salary is set at $1 million. The filing also outlines severance benefits, including salary continuation and continued option vesting, contingent on a non-compete agreement. The press release, also furnished, likely provides further context on these changes and their implications for the company's outlook.

Key Highlights

  • 1Andrew Witty has stepped down as CEO, effective May 12, 2025, and will serve as a senior advisor.
  • 2Steve Hemsley has been appointed as the new CEO, effective May 12, 2025, and will continue as Chair of the Board.
  • 3Mr. Hemsley's compensation includes a $1,000,000 annual base salary and no annual cash incentive.
  • 4A one-time equity award of $60,000,000 in nonqualified stock options, with three-year cliff vesting, has been granted to Mr. Hemsley.
  • 5Severance benefits for Mr. Hemsley include two times annual base salary and bonus, with continued option vesting for 24 months, contingent on a non-compete clause.
  • 6The company issued a press release on May 13, 2025, detailing these management changes and earnings guidance.

Frequently Asked Questions

The filing states that Andrew Witty notified the Company of his decision to step down from his position. While the specific reasons are not detailed in this 8-K, he will continue to serve as a senior advisor to the new CEO, suggesting a planned transition.

Steve Hemsley's appointment signifies a new leadership era for UnitedHealth Group. His continued role as Chair of the Board suggests a desire for continuity and experienced leadership during this transition. Investors will be looking to his strategic vision to drive future growth and performance.

Mr. Hemsley will receive an annual base salary of $1,000,000, no annual cash incentive, and a significant one-time equity award of $60,000,000 in stock options that vest after three years. This structure emphasizes long-term alignment with shareholder value.

Severance benefits are triggered by termination without cause or by Mr. Hemsley for good reason. They include two times his annual base salary and bonus, with continued vesting of stock options during a 24-month severance period, provided he adheres to a non-compete agreement for the same duration.